Epidemiology of potentially inappropriate medication use and risk for mild cognitive impairment and dementia among ARIC, Look AHEAD, and MESA
Epidemiology of potentially inappropriate medication use and risk for mild cognitive impairment and dementia among ARIC, Look AHEAD, and MESA
批准号:
10590111
负责人:
Michael Patrick Bancks
金额:
$15.5万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-01-01 至 2024-12-31
关键词:
AcetylcholineAddressAdultAdverse eventAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskAmericanAnti-CholinergicsAtherosclerosisAtherosclerosis Risk in CommunitiesBehavioralBenzodiazepinesBlack raceBrain PathologyBrain imagingCentral Nervous SystemClassificationClinicalClinical DataClinical ResearchClinical TrialsCognitiveCollectionCommunitiesDataDementiaDevelopmentDiabetes MellitusDoseElderlyEpidemiologyEventFutureGeographyGeriatricsGoalsHealthHealth BenefitHealth Care CostsHealth StatusHeart failureHispanicHospitalizationImpaired cognitionIncidenceIndividualInterventionLinkMorbidity - disease rateMulti-Ethnic Study of AtherosclerosisNatural HistoryNeurotransmittersNon-Insulin-Dependent Diabetes MellitusOutcomeOverweightParticipantPathologyPatientsPeripheral Nervous SystemPharmaceutical PreparationsPopulation HeterogeneityPositioning AttributePrevalencePublic HealthRegistriesResearchResearch PersonnelResourcesRiskSocietiesSubgroupTestingTimeUnited StatesWomanWorkadjudicationcognitive testingcohortcomorbiditydementia riskdesignepidemiologic dataepidemiology studyexperiencefollow-uphospitalization rateshuman old age (65+)innovationinsightlifestyle interventionmild cognitive impairmentmortalitymulti-ethnicobese personphenotypic dataphysical inactivitypreventracial diversityresponseskillsstructural determinantsstudy populationtreatment strategyweight loss intervention
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Use of potentially inappropriate medications (PIMs) among older adults (age ≥65 years) result in preventable
adverse health events, including hospitalization and mortality. Certain individual medications that are classified
as PIMs are associated with greater risk for dementia, demonstrated to act on the central and peripheral nervous
system and block the action of specific neurotransmitters (e.g., anticholinergics block acetylcholine). Registry-
based studies show that PIM use increases over older adulthood for individuals with Alzheimer’s disease and
related dementias (AD/RD) and matched healthy controls. However, epidemiology of PIM use over older
adulthood has not been assessed in multi-ethnic community-based cohorts or in response to a lifestyle
intervention. Because PIM use results in avoidable complications, we need to understand epidemiology of PIM
use in response to interventions and in relation to subsequent cognitive complications, respectively. Identifying
whether lifestyle interventions can reduce PIM use and prevent mild cognitive impairment and dementia would
have major clinical and public health implications.
This proposal will leverage data from epidemiological studies and a clinical trial to provide estimates of PIM
prevalence, incidence, and longitudinal change among three large multi-ethnic and geographically diverse study
populations: the Atherosclerosis Risk in Communities (ARIC) Study, Action for Health in Diabetes Study, and
Multi-Ethnic Study of Atherosclerosis. This research will estimate (Aim 1) prevalence of PIM use and factors
associated with PIM use, (Aim 2) longitudinal change in PIM use during older adulthood and in response to an
intensive lifestyle intervention for weight loss, and (Aim 3) the association between PIM use and incident
MCI/dementia and brain pathology.
This work is significant and innovative because it will provide estimates of PIM use among multi-ethnic cohorts
and a new research resource for Look AHEAD and MESA investigators (characterization of PIM use). This
proposal will also assess the effect of a lifestyle intervention on longitudinal change in PIM use and will help
disentangle the temporal association between PIM use and AD/RD. We have designed each aim to address a
critical gap in our understanding of the epidemiology of PIM use, and potential for interventions in older adulthood
to reduce AD/RD-related morbidity and mortality due to PIM use. Our team has the research skills, experience,
and resources to address these aims in a rigorous and efficient manner. The findings from this work will provide
empirical evidence for treatment strategies to reduce PIM use and prevent AD/RD, and to assess whether PIM
use is associated with other aging-related conditions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金